文献速递运动医学关节外科

原位成型纤维蛋白凝胶包裹间充质干细胞外泌体治疗兔部分层厚肩袖撕裂:在防止撕裂进展和促进愈合方面显示有效性

In Situ-Forming Fibrin Gel Encapsulation of MSC-Exosomes for Partial-Thickness Rotator Cuff Tears in a Rabbit Model: Effectiveness Shown in Preventing Tear Progression and Promoting Healing.
PubMed 文献 · J Bone Joint Surg Am · 2022-06-17

研究在56只兔(112肩)中建立50%层厚滑囊侧肩袖部分撕裂模型,分对照组、纤维蛋白组、ASC-Exos/纤维蛋白组和假手术组。术后12周,ASC-Exos/纤维蛋白组肌腱厚度和组织学评分均显著优于对照组和纤维蛋白组;局部给予原位成型ASC-Exos/纤维蛋白有效促进兔滑囊侧部分层厚肩袖撕裂愈合,可能成为非手术治疗候选方案。

要点

  • 术后12周ASC-Exos/纤维蛋白组肌腱厚度1.63±0.19 mm,显著大于对照组0.85±0.09 mm和纤维蛋白组1.16±0.17 mm(均p<0.0001)。
  • 术后12周ASC-Exos/纤维蛋白组组织学评分6.25±0.53,显著优于对照组11.38±0.72和纤维蛋白组9.00±0.54(均p<0.0001)。
  • 免疫组化I型和III型胶原染色及生物力学测试也显示ASC-Exos/纤维蛋白修复效果优于单纯纤维蛋白和无治疗。

核心结论

  • 局部给予原位成型ASC-Exos/纤维蛋白有效促进兔滑囊侧部分层厚肩袖撕裂愈合。
  • 该方法可能成为部分层厚肩袖撕裂非手术治疗的候选方案。

研究设计与样本

  • 研究纳入56只兔(112肩),分为对照组(32肩,部分层厚肩袖撕裂不治疗)、纤维蛋白组(32肩,纤维蛋白凝胶治疗)、ASC-Exos/纤维蛋白组(32肩,脂肪干细胞来源外泌体/纤维蛋白治疗)和假手术组(16肩,假手术)。
  • 用11号手术刀片在冈上肌腱建立双侧50%层厚、滑囊侧、1 mm(深)×3 mm(宽)×5 mm(长)的部分层厚肩袖撕裂,用数字游标卡尺确保测量准确性。
  • 术后6周和12周进行大体观察、残余冈上肌腱厚度测量以及组织学和生物力学分析以评估肌腱修复。

主要发现

  • 术后12周,ASC-Exos/纤维蛋白组肌腱厚度(均值±标准差,1.63±0.19 mm)显著大于对照组(0.85±0.09 mm)(p<0.0001)和纤维蛋白组(1.16±0.17 mm)(p<0.0001)。
  • 术后12周,ASC-Exos/纤维蛋白组组织学评分(6.25±0.53)显著优于对照组(11.38±0.72)(p<0.0001)和纤维蛋白组(9.00±0.54)(p<0.0001)。
  • 总体而言,I型和III型胶原的免疫组化染色及生物力学测试也显示ASC-Exos/纤维蛋白在修复部分层厚肩袖撕裂方面比单纯纤维蛋白和无治疗更有效。

临床怎么用

  • 作者认为,超声引导下注射ASC-Exos/纤维蛋白可能是一种治疗部分层厚肩袖撕裂的新型非手术策略。
  • 作者认为,该方法可能成为部分层厚肩袖撕裂非手术管理的候选方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current nonoperative treatments for partial-thickness rotator cuff tears (PTRCTs) have limited effectiveness in preventing tear progression or promoting tendon healing. This study aimed to establish a rabbit model using in situ-forming fibrin gel containing adipose stem cell-derived exosomes (ASC-Exos/fibrin) to treat PTRCTs. METHODS: Fifty-six rabbits (112 shoulders) were included in this study and assigned to 4 groups: the control group (32 shoulders; PTRCTs without treatment), the fibrin group (32 shoulders; PTRCTs treated with fibrin gel), the ASC-Exo/fibrin group (32 shoulders; PTRCTs treated with ASC-Exos/fibrin), and the sham group (16 shoulders; sham surgery). Bilateral, 50%-thickness, bursal-side PTRCTs of 1 mm (depth) × 3 mm (width) × 5 mm (length) on the supraspinatus tendon were established by a number-11 scalpel blade, with accuracy of the measurement ensured by a digital vernier caliper. At 6 and 12 weeks postoperatively, gross observation, measurement of the thickness of residual supraspinatus tendons, and histological and biomechanical analyses were performed to analyze tendon repair. RESULTS: At 12 weeks postoperatively, the tendon thickness in the ASC-Exos/fibrin group (mean and standard deviation, 1.63 ± 0.19 mm) was significantly greater than in the control group (0.85 ± 0.09 mm) (p < 0.0001) and fibrin group (1.16 ± 0.17 mm) (p < 0.0001). The histological score in the ASC-Exos/fibrin group (6.25 ± 0.53) was significantly better than in the control group (11.38 ± 0.72) (p < 0.0001) and fibrin group (9.00 ± 0.54) (p < 0.0001). Overall, immunohistochemical staining of types-I and III collagen and biomechanical testing also showed ASC-Exos/fibrin to be more effective in repairing PTRCTs than fibrin alone and no treatment. CONCLUSIONS: Local administration of in situ-forming ASC-Exos/fibrin effectively facilitated the healing of bursal-side PTRCTs in rabbits. This approach may be a candidate for the nonoperative management of PTRCTs. CLINICAL RELEVANCE: Ultrasound-guided injection of ASC-Exos/fibrin may be a novel nonoperative strategy to treat PTRCTs.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Wang C, Tan J, Zhang Y, et al. In Situ-Forming Fibrin Gel Encapsulation of MSC-Exosomes for Partial-Thickness Rotator Cuff Tears in a Rabbit Model: Effectiveness Shown in Preventing Tear Progression and Promoting Healing. J Bone Joint Surg Am. 2022. PMID: 35726973. doi:10.2106/JBJS.21.01157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。